IL2 and neuroblastoma: Despite these limitations, our findings demonstrate that single-agent dinutuximab beta (i.e., without IL-2 and isotretinoin) administered by long-term, continuous infusion in patients with relapsed/refractory HR-NB was associated with improved tolerability and clinically significant and durable response rates that translated into encouraging three-year PFS and OS rates.